To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Department of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece.
Early Clinical Trials Unit, Antwerp University Hospital, Antwerp, Belgium.
Leeds Institute of Medical Research at St James' Hospital, University of Leeds, Leeds, United Kingdom.
Show others and affiliations
2020 (English)In: Frontiers in Oncology, E-ISSN 2234-943X, Vol. 10, article id 575148Article, review/survey (Refereed) Published
Abstract [en]

Introduction: Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support decision making, pertaining to the oncologic care in the middle of a global outbreak.

Methods: We did an international online search in twenty five countries that have managed a surge in cancer patient numbers. We collected the recommendations from thirty one medical oncology societies.

Results: By synthesizing guidelines for a) oncology service delivery adjustments, b) general and specific treatment adaptations, and c) discrepancies from guidelines comparison, we present a clinical synopsis with the forty more crucial statements. A Covid-19 risk stratification base was also created in order to obtain a quick, objective patient assessment and a risk-benefit evaluation on a case-by-case basis.

Conclusions: In an attempt to face these complex needs and due to limited understanding of COVID-19, a variability of recommendations based on general epidemiological and infectious disease principles rather than definite cancer-related evidence has evolved. Additionally, the absence of an effective treatment or vaccine requires the development of cancer management guidance, capitalizing on comprehensive COVID-19 oncology experience globally.

Place, publisher, year, edition, pages
Frontiers , 2020. Vol. 10, article id 575148
Keywords [en]
Covid-19, international, oncology, recommendations, societies
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-88140DOI: 10.3389/fonc.2020.575148ISI: 000595107700001PubMedID: 33330049Scopus ID: 2-s2.0-85097297192OAI: oai:DiVA.org:oru-88140DiVA, id: diva2:1511308
Available from: 2020-12-18 Created: 2020-12-18 Last updated: 2024-01-17Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Valachis, Antonis

Search in DiVA

By author/editor
Valachis, Antonis
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Frontiers in Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 79 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf